If the burden of cost sharing no longer fell on cancer patients, they would be more likely to access care and maintain treatment as prescribed, leading to improved outcomes, according to Samantha Watson, founder and CEO of The Samfund. When faced with high copays, patients are more likely to skip appointments or take only half of their prescribed medications.
If the burden of cost sharing no longer fell on cancer patients, they would be more likely to access care and maintain treatment as prescribed, leading to improved outcomes, according to Samantha Watson, founder and CEO of The Samfund. When faced with high copays, patients are more likely to skip appointments or take only half of their prescribed medications.
Transcript (slightly modified)
How would the elimination of cost sharing affect the experiences of cancer patients?
I don’t know enough about, sort of, the mechanics of cost sharing and what eliminating cost sharing would do to the whole system, but I know that for cancer patients, it wouldn’t suddenly be a free-for-all where everybody was getting more than they needed, because what we see in the young adult population is that young adults just aren’t going to their appointments because they can’t afford it.
If the burden of cost sharing no longer fell on the patient, they would have better access to care. I think young adults, a lot of times when they show at the pharmacy for example and have a very high copay, 1 of 2 things happens. Either they take the medication and they just start taking it half as prescribed because they can’t afford to fill that prescription as often as prescribed, or they skip it.
If they didn’t face that high copay, potentially, they’d be able to take their meds as prescribed, and we all know that that would be better in the long run. So I think, again I don’t know about the larger question of what that would mean, but the impact on the individual would mean that people would be able to get the care that they need.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More